Transimmune

Düsseldorf, Germany

Transimmune is a pioneering dendritic cell therapy business that has discovered how dendritic cells are produced biologically.

$5.0M raised

Sep 2023

Seed

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Transimmune raised?

Transimmune has raised $5.0M in total funding. The most recent round was Seed. The last funding was announced in September 2023.

Who are Transimmune's investors?

Transimmune's investors include Bill & Melinda Gates Foundation.

Where is Transimmune headquartered?

Transimmune is headquartered in Düsseldorf, Germany.

What does Transimmune do?

Transimmune is a pioneering dendritic cell therapy business that has discovered how dendritic cells are produced biologically.

What stage is Transimmune at?

Transimmune is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 20, 2023.

MLA

"Transimmune — Funding & Investors." VCBacked, September 20, 2023, https://www.vcbacked.co/company/transimmune. Accessed July 2, 2026.

APA

VCBacked. (2023). Transimmune — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/transimmune

Wikipedia (cite web)

{{cite web |title=Transimmune — Funding & Investors |url=https://www.vcbacked.co/company/transimmune |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 20, 2023.